Shengfang Jin

9.6k total citations · 2 hit papers
21 papers, 5.8k citations indexed

About

Shengfang Jin is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Shengfang Jin has authored 21 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 7 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Shengfang Jin's work include Cancer, Hypoxia, and Metabolism (7 papers), Glioma Diagnosis and Treatment (5 papers) and DNA Repair Mechanisms (3 papers). Shengfang Jin is often cited by papers focused on Cancer, Hypoxia, and Metabolism (7 papers), Glioma Diagnosis and Treatment (5 papers) and DNA Repair Mechanisms (3 papers). Shengfang Jin collaborates with scholars based in United States, China and Canada. Shengfang Jin's co-authors include Shinsan M. Su, Lenny Dang, Valeria R. Fantin, Stefan Größ, Mark Bittinger, Hyun Gyung Jang, Edward M. Driggers, David T. Weaver, Katharine Yen and Marie C. Keenan and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Shengfang Jin

18 papers receiving 5.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

2009 3.1k citations Lenny Dang, David W. White et al. Nature profile →
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

2010 558 citations Stefan Größ, Rob A. Cairns et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shengfang Jin United States	16	3.9k	2.5k	1.7k	785	766	21	5.8k
Stefan Größ United States	17	3.5k 0.9×	2.8k 1.1×	1.8k 1.1×	691 0.9×	570 0.7×	27	5.5k
Mark Bittinger United States	14	2.8k 0.7×	2.1k 0.8×	1.5k 0.9×	594 0.8×	587 0.8×	20	4.6k
Shinsan M. Su United States	13	4.4k 1.1×	3.5k 1.4×	2.4k 1.4×	1.4k 1.7×	658 0.9×	16	6.9k
Katharine Yen United States	22	3.6k 0.9×	2.8k 1.1×	2.1k 1.2×	1.2k 1.6×	662 0.9×	38	5.9k
Kevin M. Marks United States	9	2.6k 0.7×	1.8k 0.7×	1.3k 0.8×	417 0.5×	454 0.6×	14	4.2k
David R. Wise United States	15	4.3k 1.1×	3.8k 1.5×	648 0.4×	559 0.7×	799 1.0×	48	6.3k
Marie C. Keenan United States	6	2.6k 0.7×	2.0k 0.8×	1.3k 0.8×	414 0.5×	401 0.5×	8	4.1k
Lenny Dang United States	26	5.0k 1.3×	3.7k 1.5×	2.3k 1.3×	1.4k 1.7×	1.5k 1.9×	50	8.3k
Valeria R. Fantin United States	32	6.9k 1.8×	4.8k 1.9×	2.7k 1.6×	1.3k 1.6×	1.5k 2.0×	55	11.0k
Genglin Jin United States	15	3.0k 0.8×	2.4k 1.0×	3.3k 1.9×	246 0.3×	666 0.9×	22	5.8k

Countries citing papers authored by Shengfang Jin

Since Specialization

Citations

This map shows the geographic impact of Shengfang Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengfang Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengfang Jin more than expected).

Fields of papers citing papers by Shengfang Jin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengfang Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengfang Jin. The network helps show where Shengfang Jin may publish in the future.

Co-authorship network of co-authors of Shengfang Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Shengfang Jin. A scholar is included among the top collaborators of Shengfang Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengfang Jin. Shengfang Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Banerjee, Daliya, Jingyan Gao, Fei Pang, et al.. (2025). Abstract P4-12-29: ETX-197/BG-68501, a potential best-in-class potent, selective, oral, small molecule CDK2 inhibitor, has anti-tumor activity in cancer models with Cyclin E amplification or deficiency in the Retinoblastoma 1 gene. Clinical Cancer Research. 31(12_Supplement). P4–12.

Koncar, Robert F., Jingyan Gao, Fei Pang, et al.. (2025). Abstract 1659: ETX-636, a novel allosteric pan-mutant-selective PI3Kα dual inhibitor and degrader with best-in-class potential. Cancer Research. 85(8_Supplement_1). 1659–1659.

Jin, Shengfang, et al.. (2023). Enhanced Segmentation of PV Arrays in Infrared Images using an Improved SegFormer Approach. 3914–3920.

Pirman, David, et al.. (2019). Metabolic analysis reveals evidence for branched chain amino acid catabolism crosstalk and the potential for improved treatment of organic acidurias. Molecular Genetics and Metabolism. 128(1-2). 57–61. 13 indexed citations

Calabria, Andrea, María García‐Bravo, Fabrizio Benedicenti, et al.. (2016). Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency. Molecular Therapy. 24(7). 1187–1198. 43 indexed citations

Chan, Barden, Michelle Clasquin, Gromoslaw A. Smolen, et al.. (2016). A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2. Human Molecular Genetics. 25(11). 2182–2193. 33 indexed citations

Allen, Eric L., Danielle Ulanet, David Pirman, et al.. (2016). Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. Cell Reports. 17(3). 876–890. 53 indexed citations

Popovici-Müller, Janeta, Jeffrey O. Saunders, Francesco G. Salituro, et al.. (2012). Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. ACS Medicinal Chemistry Letters. 3(10). 850–855. 160 indexed citations

Größ, Stefan, Rob A. Cairns, Mark D. Minden, et al.. (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. The Journal of Experimental Medicine. 207(2). 339–344. 558 indexed citations breakdown →

10.

Fantin, Valeria R., Lenny Dang, David W. White, et al.. (2010). Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Cancer Research. 70(8_Supplement). 33–33. 4 indexed citations

11.

Dang, Lenny, Shengfang Jin, & Shinsan M. Su. (2010). IDH mutations in glioma and acute myeloid leukemia. Trends in Molecular Medicine. 16(9). 387–397. 275 indexed citations

12.

Dang, Lenny, David W. White, Stefan Größ, et al.. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462(7274). 739–744. 3067 indexed citations breakdown →

13.

Livingstone, Mark, Hong Ruan, Karl R. Clauser, et al.. (2005). Valosin-Containing Protein Phosphorylation at Ser784 in Response to DNA Damage. Cancer Research. 65(17). 7533–7540. 55 indexed citations

14.

Perry, William L., Robert L. Shepard, Janardhan Sampath, et al.. (2005). Human Splicing Factor SPF45 (RBM17) Confers Broad Multidrug Resistance to Anticancer Drugs When Overexpressed— a Phenotype Partially Reversed By Selective Estrogen Receptor Modulators. Cancer Research. 65(15). 6593–6600. 38 indexed citations

15.

Bharti, Ajit, Stine‐Kathrein Kraeft, Mrinal M. Gounder, et al.. (1998). Inactivation of DNA-Dependent Protein Kinase by Protein Kinase Cδ: Implications for Apoptosis. Molecular and Cellular Biology. 18(11). 6719–6728. 188 indexed citations

16.

Kumar, Shailendra, Pramod S. Pandey, Ajit Bharti, et al.. (1998). Regulation of DNA-dependent Protein Kinase by the Lyn Tyrosine Kinase. Journal of Biological Chemistry. 273(40). 25654–25658. 33 indexed citations

17.

Kharbanda, Surender, Pramod S. Pandey, Shengfang Jin, et al.. (1997). Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature. 386(6626). 732–735. 208 indexed citations

18.

Jin, Shengfang, Surender Kharbanda, Bruce J. Mayer, Donald Küfe, & David T. Weaver. (1997). Binding of Ku and c-Abl at the Kinase Homology Region of DNA-dependent Protein Kinase Catalytic Subunit. Journal of Biological Chemistry. 272(40). 24763–24766. 81 indexed citations

19.

Gu, Yansong, Shengfang Jin, Yijie Gao, David T. Weaver, & Frederick W. Alt. (1997). Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proceedings of the National Academy of Sciences. 94(15). 8076–8081. 343 indexed citations

20.

Milne, G. Todd, Shengfang Jin, Katie B. Shannon, & David T. Weaver. (1996). Mutations in Two Ku Homologs Define a DNA End-Joining Repair Pathway in Saccharomyces cerevisiae. Molecular and Cellular Biology. 16(8). 4189–4198. 241 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact